We hypothesized that biomarkers of extracellular matrix remodeling, quantified by MMP-degraded biglycan, BGM, cathepsin S-degraded nidogen, NIC, and MMP-degraded SPARC (SPARC-M) could be diagnostic biomarkers in patients with MS. The gene discussed is SPARC; the disease is myeloid sarcoma.